Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 12 (December)

1. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.
   J Nucl Med, 50(12): 2042-8. [Abstract] [Full-text]
2. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
   J Nucl Med, 50(12): 2017-24. [Abstract] [Full-text]
3. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.
   Cancer Cell, 16(6): 487-97. [Abstract] [Full-text]
4. Steroid hormone receptors in prostate cancer: a hard habit to break?
   Cancer Cell, 16(6): 458-62. [Abstract] [Full-text]
5. Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer.
   Urology, 74(6): 1296-302. [Abstract] [Full-text]
6. A patient recall program to enhance decisions about prostate cancer screening: a feasibility study.
   BMC Fam Pract, 10: 75. [Abstract] [Full-text]
7. Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.
   BMC Med Inform Decis Mak, 9: 47. [Abstract] [Full-text]
8. Induced chromosomal proximity and gene fusions in prostate cancer.
   Science, 326(5957): 1230. [Abstract] [Full-text]
9. Validation of two preoperative Kattan nomograms predicting recurrence after radical prostatectomy for localized prostate cancer in Turkey: a multicenter study of the Uro-oncology Society.
   Urology, 74(6): 1289-95. [Abstract] [Full-text]
10. Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon.
    Urology, 74(6): 1183-90. [Abstract] [Full-text]
11. Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence.
    J Clin Oncol, 27(35): 6000-5. [Abstract] [Full-text]
12. Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.
    Br J Cancer, 101(12): 2043-7. [Abstract] [Full-text]
13. Epac inhibits migration and proliferation of human prostate carcinoma cells.
    Br J Cancer, 101(12): 2038-42. [Abstract] [Full-text]
14. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.
    Br J Cancer, 101(12): 1949-56. [Abstract] [Full-text]
15. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Int J Radiat Oncol Biol Phys, 76(1): 50-6. [Abstract] [Full-text]
16. Gene networks and microRNAs implicated in aggressive prostate cancer.
    Cancer Res, 69(24): 9490-7. [Abstract] [Full-text]
17. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer.
    Cell, 139(6): 1069-83. [Abstract] [Full-text]
18. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.
    Cancer Res, 69(24): 9448-56. [Abstract] [Full-text]
19. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study.
    Cancer Res, 69(24): 9315-22. [Abstract] [Full-text]
20. Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.
    Cancer Res, 69(24): 9465-72. [Abstract] [Full-text]
21. Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer.
    J Urol, 183(1): 345-50. [Abstract] [Full-text]
22. The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted.
    J Urol, 183(1): 151-7. [Abstract] [Full-text]
23. Impact of positive surgical margins after radical prostatectomy differs by disease risk group.
    J Urol, 183(1): 145-50. [Abstract] [Full-text]
24. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
    J Urol, 183(1): 112-6. [Abstract] [Full-text]
25. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort.
    J Urol, 183(1): 138-43. [Abstract] [Full-text]
26. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.
    J Urol, 183(1): 126-31. [Abstract] [Full-text]
27. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen.
    J Urol, 183(1): 118-24. [Abstract] [Full-text]
28. Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer.
    J Urol, 183(1): 133-7. [Abstract] [Full-text]
29. Validation of the partin nomogram for prostate cancer in a national sample.
    J Urol, 183(1): 105-11. [Abstract] [Full-text]
30. Hypofractionation: what does it mean for prostate cancer treatment?
    Int J Radiat Oncol Biol Phys, 76(1): 260-8. [Abstract] [Full-text]
31. Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread.
    Oncogene, 28(49): 4344-52. [Abstract] [Full-text]
32. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Int J Radiat Oncol Biol Phys, 76(1): 269-76. [Abstract] [Full-text]
33. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
    Int J Radiat Oncol Biol Phys, 76(1): 14-22. [Abstract] [Full-text]
34. Brachytherapy or conformal external radiotherapy for prostate cancer: a single-institution matched-pair analysis.
    Int J Radiat Oncol Biol Phys, 76(1): 43-9. [Abstract] [Full-text]
35. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
    Int J Radiat Oncol Biol Phys, 76(1): 36-42. [Abstract] [Full-text]
36. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Int J Radiat Oncol Biol Phys, 76(1): 57-64. [Abstract] [Full-text]
37. Time of decline in sexual function after external beam radiotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 76(1): 31-5. [Abstract] [Full-text]
38. Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.
    Int J Radiat Oncol Biol Phys, 76(1): 23-30. [Abstract] [Full-text]
39. Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer.
    Int J Cancer, 126(2): 315-27. [Abstract] [Full-text]
40. Kallikrein-related peptidase-4 initiates tumor-stroma interactions in prostate cancer through protease-activated receptor-1.
    Int J Cancer, 126(3): 599-610. [Abstract] [Full-text]
41. Enhanced antiproliferative and proapoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-dependent protein kinase A.
    Int J Cancer, 126(3): 775-89. [Abstract] [Full-text]
42. Adeno-associated virus-delivered short hairpin-structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study.
    Int J Cancer, 126(3): 764-74. [Abstract] [Full-text]
43. Palliation of malignant rectal obstruction from invasive prostate cancer with multiple overlapping self-expanding metal stents.
    South Med J, 102(12): 1257-9. [Abstract] [Full-text]
44. The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts.
    Oncogene, 28(50): 4480-90. [Abstract] [Full-text]
45. Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer.
    Eur J Endocrinol, 162(1): 177-81. [Abstract] [Full-text]
46. High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2.
    AJR Am J Roentgenol, 194(1): W33-7. [Abstract] [Full-text]
47. Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.
    Am J Epidemiol, 171(1): 1-13. [Abstract] [Full-text]
48. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.
    Am J Surg Pathol, 34(1): 35-43. [Abstract] [Full-text]
49. Tumor suppressor PAX6 functions as androgen receptor co-repressor to inhibit prostate cancer growth.
    Prostate, 70(2): 190-9. [Abstract] [Full-text]
50. Antisense oligonucleotide targeting of insulin-like growth factor-1 receptor (IGF-1R) in prostate cancer.
    Prostate, 70(2): 206-18. [Abstract] [Full-text]
51. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.
    Prostate, 70(2): 219-27. [Abstract] [Full-text]
52. PTEN-mediated G1 cell-cycle arrest in LNCaP prostate cancer cells is associated with altered expression of cell-cycle regulators.
    Prostate, 70(2): 135-46. [Abstract] [Full-text]
53. Radical prostatectomy: influence on serum and urinary androgen levels.
    Prostate, 70(2): 200-5. [Abstract] [Full-text]
54. No association between variant DNA repair genes and prostate cancer risk among men of African descent.
    Prostate, 70(2): 113-9. [Abstract] [Full-text]
55. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
    Prostate, 70(2): 170-8. [Abstract] [Full-text]
56. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
    Prostate, 70(2): 155-61. [Abstract] [Full-text]
57. Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer.
    Prostate, 70(2): 162-9. [Abstract] [Full-text]
58. PSA and body composition by dual X-ray absorptiometry (DXA) in NHANES.
    Prostate, 70(2): 120-5. [Abstract] [Full-text]
59. Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model.
    Prostate, 70(2): 147-54. [Abstract] [Full-text]
60. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells.
    Int J Cancer, 126(4): 810-8. [Abstract] [Full-text]
61. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
    J Clin Oncol, 28(1): 126-31. [Abstract] [Full-text]
62. Localization of candidate genes in a region of high frequency of microvariant alleles for prostate cancer susceptibility: the chromosome region Yp11.2 genetic variation.
    DNA Cell Biol, 29(1): 3-7. [Abstract] [Full-text]
63. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival.
    Clin Chem, 56(1): 34-43. [Abstract] [Full-text]
64. New developments in the medical management of prostate cancer.
    Mayo Clin Proc, 85(1): 77-86. [Abstract] [Full-text]

© 2004-2010 Prostate Cancer Research Today. All Rights Reserved.